^
    1d
    TRIFOUR: Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. (clinicaltrials.gov)
    P1/2, N=117, Active, not recruiting, Cantargia AB | Trial primary completion date: Jun 2025 --> Apr 2026
    Trial primary completion date • BRCA Companion diagnostic • PARP Companion diagnostic
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • CD4 (CD4 Molecule)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • HER-2 negative + HR negative • HER-2 negative + HR negative + BRCA mutation
    |
    PD-L1 IHC 22C3 pharmDx • Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    carboplatin • gemcitabine • nadunolimab (CAN04)
    9d
    Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours (clinicaltrials.gov)
    P3, N=11000, Active, not recruiting, University College, London | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HR positive • HER-2 negative • HR negative • ER negative • HER-2 negative + ER positive • HER-2 negative + HR negative
    |
    aspirin
    9d
    GIM25-CAPT: A Phase II trial of atezolizumab plus CArboplatin plus nab-Paclitaxel as first-line Therapy in metastatic triple-negative PD-L1 positive breast cancer patients (2024-519514-31-00)
    P1/2, N=104, Recruiting, Consorzio Oncotech | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 negative • HR negative • HER-2 negative + HR negative
    |
    VENTANA PD-L1 (SP142) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • albumin-bound paclitaxel
    11d
    Prognosis of Pregnancy-Associated Breast Cancer: A Systematic Review of Contemporary Observational Studies. (PubMed, Med Sci (Basel))
    Current evidence suggests that pregnancy itself does not inevitably worsen breast cancer prognosis when treatment is not compromised. However, breast cancers diagnosed soon after childbirth represent a distinct high-risk subgroup. These findings support full-intensity, guideline-based therapy during pregnancy and highlight the need for special attention and further research focused on postpartum breast cancer.
    Observational data • Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 negative • HR negative • HER-2 negative + HR negative • HR negative + HER-2 positive
    1m
    A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation (clinicaltrials.gov)
    P2, N=26, Not yet recruiting, Hu Hai
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)
    |
    HER-2 amplification • HER-2 negative • PIK3CA mutation • HER-2 negative + HR negative
    |
    Halaven (eribulin mesylate) • Itovebi (inavolisib)
    2ms
    FACT-TN: FMD and Neoadjuvant Chemo-immunotherapy in TNBC (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 negative + ER positive • HER-2 negative + HR negative
    |
    docetaxel • Loqtorzi (toripalimab-tpzi) • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    2ms
    BNT326-01: A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors (clinicaltrials.gov)
    P1/2, N=980, Recruiting, BioNTech SE | N=550 --> 980 | Trial completion date: Feb 2030 --> Oct 2029 | Trial primary completion date: May 2028 --> Feb 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • HR positive • BRAF mutation • HER-2 negative • EGFR L858R • HER-2 expression • EGFR exon 19 deletion • ALK rearrangement • PD-L1 expression + HER-2 overexpression • HER-2 negative + HR negative
    |
    itraconazole • pumitamig (BNT327)
    3ms
    Modern Management of the Axilla in HER2-Negative Hormone Receptor-Positive Early Breast Cancer Upfront Surgery: Toward De-Escalation and Individualization. (PubMed, Cancers (Basel))
    In conclusion, modern axillary management in HR-positive, HER2-negative breast cancer involves navigating the intersection between de-escalated surgery and risk-adapted systemic therapy. Future strategies should prioritize individualized care, incorporating tumor biology, imaging findings, and patient preferences, with multidisciplinary collaboration playing a central role in optimizing outcomes.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HER-2 negative + HR negative
    3ms
    IMMCO-1: Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types (clinicaltrials.gov)
    P1/2, N=29, Suspended, University of Florida | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • CD4 (CD4 Molecule)
    |
    HER-2 positive • HER-2 negative • HER-2 negative + HR negative • HR negative + HER-2 positive
    |
    Tecentriq (atezolizumab) • Fotivda (tivozanib)
    3ms
    Impact of Socioeconomic Factors on Surgical Approach and Outcomes in Young Women with Breast Cancer. (PubMed, Eur J Breast Health)
    Young Black women were more likely than White women to elect the less-invasive surgery (lumpectomy). Private insurance was associated with better OS and RFS.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • EGFR positive • HR positive + HER-2 negative • HR positive + HER-2 positive • HER-2 negative + HR negative
    4ms
    A-Brave: Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab (clinicaltrials.gov)
    P3, N=474, Completed, Istituto Oncologico Veneto IRCCS | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 amplification • HER-2 negative • HR negative • HER-2 negative + HR negative
    |
    Bavencio (avelumab)
    4ms
    The plasma nanoDSF denaturation profiles predict the presence of breast cancer. (PubMed, J Transl Med)
    We reveal the potential of nanoDSF and AI applied to plasma samples to discriminate between BC patients and HC. If these results are confirmed, such approach could represent a minimally-invasive, low risk, quick and low-cost technique, which could help to improve the screening of BC.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HER-2 negative + HR negative